Zhejiang Medicine Co Ltd (600216) Cash Flow Statement

A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.

Zhejiang Medicine Co., Ltd. manufactures and sells life nutrition and pharmaceuticals products in China and internationally. The company offers synthetic vitamin E, vitamin A, natural vitamin E, ß-carotene, canthaxanthin, vancomycin hydrochloride, teicoplanin, and daptomycin.

Total Cash From Operating Activities Chart for Zhejiang Medicine Co Ltd

Zhejiang Medicine Co Ltd (600216) operating cash flow for FY2025 was CNY 1.9B, a 54.2% change from FY2024. Zhejiang Medicine Co Ltd's operating cash flow grew from CNY 57.7M in 1998 to CNY 1.9B in 2025 (3167.3% over 27 years). Operating cash flow compound annual growth rate: 5-year CAGR of 8.5%, 10-year CAGR of 33.3%, 20-year CAGR of 24.1%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Cash From Operating Activities (CNY)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
¥10.22B
Implied Share Price
¥10.63
Enterprise Value
¥7.37B
Revenue (TTM)
¥8.43B
EBITDA
¥1.32B
Profit Margin
7.51%
Trailing P/E
16.11
Forward P/E
13.39
Price/Book (MRQ)
0.89
Price/Sales (TTM)
1.21
EV/EBITDA
12.39
EV/Revenue
0.87
Dividend Yield
2.64%
Book Value
¥11.84
Free Cash Flow (FY2025)
¥1.44B
Free Cash Flow Yield
14.08%

Snapshot as of 30th October 2026 — not point-in-time controlled, may lag the live market by a few days.